We, therefore, hypothesized that, in breast cancers, low GLUT3 levels could be a marker of such anti-tumour activity of RIP140 and therefore, that RIP140 might be associated with an increased overall survival for patients with tumor expressing a reduced level of GLUT3, as a surrogate of RIP140 anti-tumor activity. This evidence concerns the gene SLC2A3 and breast carcinoma.